UNICYCIVE THERAPEUTICS, INC. Fair Value, Option, Changes in Fair Value, Gain (Loss)
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Fair Value, Option, Changes in Fair Value, Gain (Loss) of $14.40 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueOptionChangesInFairValueGainLoss1 · last filed 2026-05-12
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for the quarter ending 2026-03-31 was $14.40M, a 27069.81% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for the quarter ending 2025-12-31 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for the quarter ending 2025-09-30 was $2.75M.
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for the quarter ending 2025-06-30 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for fiscal 2025 was $2.80M, a 0.00% change from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for fiscal 2024 was $2.80M, a 50.88% decline from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. fair value, option, changes in fair value, gain (loss) for fiscal 2023 was $5.70M.
| Period end | Fair Value, Option, Changes in Fair Value, Gain (Loss) 3 month | Fair Value, Option, Changes in Fair Value, Gain (Loss) 6 month | Fair Value, Option, Changes in Fair Value, Gain (Loss) 9 month | Fair Value, Option, Changes in Fair Value, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $14.40M 10-Q · filed 2026-05-12 | $14.40M derived: sum of 2 quarters · filed 2026-05-12 | $17.15M derived: sum of 3 quarters · filed 2026-05-12 | $17.15M derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.75M derived: sum of 2 quarters · filed 2026-03-30 | $2.75M derived: sum of 3 quarters · filed 2026-03-30 | $2.80M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.75M derived: sum of 2 quarters · filed 2025-11-12 | $2.80M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $53.00K 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $53.00K 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $2.80M 10-K · filed 2025-03-31 | |||
| 2023-12-31 | $5.70M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |